SCHEMBL4383585

SCHEMBL4383585

COC(=O)c1ccc(OC)c(-n2c(C)cc(O)cc2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.45
LMNA P02545 3/20 0.44
KMT2A Q03164 3/20 0.42
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41
CA14 Q9ULX7 3/20 0.41
XDH P47989 1/20 0.41
MAPK1 P28482 2/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK14 Q16539 1/20 0.41
CYP2C9 P11712 1/20 0.40
MEN1 O00255 2/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706645 0.87 ALDH1A1 (0.60) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL4466843 0.85 ALDH1A1 (0.45) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL4378519 0.85 ALDH1A1 (0.45) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL4387429 0.84 ALDH1A1 (0.47) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL27621545 0.84 ALDH1A1 (0.52) MAPTALDH1A1LMNACA12CA1
SCHEMBL4378061 0.82 ALDH1A1 (0.43) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL4380059 0.82 CYP1A2 (0.49) MAPTALDH1A1LMNAKMT2ACA12
SCHEMBL4377003 0.80 ALDH1A1 (0.53) MAPTALDH1A1LMNACA12CA1
SCHEMBL4377764 0.79 ALDH1A1 (0.52) ALDH1A1LMNACA12CA1CA2
SCHEMBL4379220 0.77 ALDH1A1 (0.50) MAPTALDH1A1LMNACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPT 2803/4885ALDH1A1 787/4885LMNA 1815/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPT 2543/4885ALDH1A1 741/4885LMNA 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.